Analysts Opinion Summary on: Achaogen, Inc. (AKAO)

The firm presently has a "buy" rating on the biopharmaceutical company's stock. Following the EPS trend, pool of analysts gave current quarter Per-Share Earnings estimates trends of $-0.01 for the PPHM while maintaining high price target of 2 and average of 2, as declared by WSJ.

Other research analysts have also issued research reports about the stock. Finally, Zacks Investment Research upgraded shares of Achaogen from a "hold" rating to a "buy" rating and set a $17.00 target price on the stock in a research note on Monday, January 9th.

Achaogen Inc closed down -2.85 points or -11.29% at $22.4 with 48,40,644 shares getting traded on Wednesday.

Total shares held by institutions as of the most recent company filings are 30,663,073 with a reported 11,679,830 bought and 249,284 sold. The company's shares were given away at $22.76 per share worth to an income of some $9,992 on account of Sarpangal Zeryn. Stock has got OUTPERFORM rating from 5 analysts of Thomson Reuters. They now have a United States dollars 27 price target on the stock.

According to, Carr is a 5-star analyst with an average return of 10.8% and a 47.1% success rate. The last stock price is up 126.69% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. The highest price target outlook for the stock is $31 and the minimum price target estimate is $25. The firm's market cap is $661.02 million.

Achaogen, Inc. (NASDAQ:AKAO) has a market capitalization of 881.89 Million. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.55. The business earned $10.73 million during the quarter, compared to analyst estimates of $13.33 million. During the same quarter a year ago, the firm posted ($0.61) earnings per share. On average, equities analysts predict that Achaogen will post ($2.22) EPS for the current year. The stock was bought at an average cost of $13.50 per share, with a total value of $6,750,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. (NASDAQ:AKAO) traded with the volume of 4.84 Million in the previous trading session. Corporate insiders own 13.80% of the company's stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Redmile Group LLC bought a new stake in shares of Achaogen during the third quarter worth $155,000.

Achaogen, Inc. (NASDAQ:AKAO) now has a consensus Price Target of $28.75. Ellington Management Group LLC purchased a new stake in Achaogen during the fourth quarter worth $391,000. Finally, Baker BROS. Advisors LP bought a new stake in shares of Achaogen during the third quarter worth $479,000. The company has development services agreement with ARK Diagnostics, co-develop an in vitro assay to measure levels of plazomicin in the blood to enable patients to receive safe and efficacious doses of plazomicin; and license agreement with Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae.



Other news